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Abstract  
Objective: To present ways to graphically represent a number needed to treat (NNT) in 
(network) meta-analysis (NMA). 
Study Design and Setting: A barrier to using NNT in NMA when an odds ratio (OR) or 
risk ratio (RR) is used is the determination of a single control event rate (). We discuss 
approaches to calculate a , and illustrate six graphical methods for NNT from NMA. 
We illustrate the graphical approaches using a NMA of cognitive enhancers for 
Alzheimer’s dementia. 
Results: The NNT calculation using a relative effect measure, such as OR and RR, 
requires a  value, but different s, including mean  across studies, pooled  
in meta-analysis, and expert opinion-based  may result in different NNTs. A NNT 
from NMA can be presented in a bar plot, Cates plot or forest plot for a single outcome, 
and a bubble plot, scatterplot or rank-heat plot for ≥2 outcomes. Each plot is associated 
with different properties and can serve different needs.  
Conclusion: Caution is needed in NNT interpretation, as considerations such as selection 
of effect size and , and  assumption across multiple comparisons, may impact 
NNT and decision-making. The proposed graphs are helpful to interpret NNTs calculated 
from (network) meta-analyses. 
Keywords: multiple treatment meta-analysis; multiple outcomes; number needed to harm; 
rank-heat plot; graphical displays; presentation results  
Word Count: #200 (abstract), #5,265 (main text), 6 figures, 1 supplementary file 
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Key Findings: 
• The number needed to treat (NNT) is an absolute measure of effect used to communicate 
the effectiveness or safety of an intervention and is frequently used in the meta-analytical 
literature. 
What this adds to what is known: 
• Different considerations of calculating a NNT in both pairwise and network meta-analysis 
(NMA), including effect size and assumptions for the control event rate across multiple 
comparisons, may impact NNT results. We present potential ways of calculating NNT in 
(network) meta-analysis, such as mean control event rate () across studies, pooled  
in meta-analysis, expert opinion-based , and range of possible . 
What is the implication? 
• The graphical representation of NNTs from NMA is crucial to ease interpretation of results. 
We present six graphical approaches for NNT from NMA and discuss their properties. We 
suggest the NNT graphical representation in a bar plot, Cates plot or forest plot for a single 
outcome, and in a bubble plot, scatterplot or rank-heat plot for at least two outcomes.  
What should change now? 
• Different plots can be used for different needs. For example, if uncertainty around NNT 
should be considered in decision-making, then a bar plot or a forest plot can be used. When 
multiple outcomes need to be considered, then a rank-heat plot is suggested. For 
communication purposes the Cates plot is suggested if the corresponding effect estimate is 
statistically significant and the confidence interval is not too wide. 
What is New? 
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1. Introduction 1 
The number needed to treat (NNT) is an absolute measure of effect used to 2 
communicate the effectiveness or safety of an intervention [1]. The NNT was first 3 
introduced to describe the absolute effect of a certain intervention versus a standard 4 
treatment or control in randomized clinical trials [2] and then was adopted in systematic 5 
reviews and meta-analyses [3]. The NNT provides insight into the clinical relevance of an 6 
effect size because it is defined as the average number of patients who need to be treated to 7 
prevent one extra person from having a bad outcome compared to another treatment. For 8 
positive outcomes, the NNT can be equivalently defined as the number of people that need 9 
to be treated to have one person with a good outcome. Similarly, the number needed to 10 
harm (NNH) indicates how many people need to be treated in order for one patient to have 11 
a particular adverse effect. To avoid the unfavorable NNH term, Altman [4] suggested the 12 
terms ‘number needed to treat for an additional beneficial outcome’ (NNTB) and and 13 
‘number needed to treat for an additional harmful outcome’ (NNTH), respectively, instead 14 
of using NNT and NNH to show direction of effect.  In this paper, we use the terms NNTB 15 
and NNTH. 16 
The NNTB and NNTH are calculated by taking the inverse of the risk difference 17 
(RD) [2], yet can also be calculated using other effect measures, such as the odds ratio 18 
(OR) and risk ratio (RR) [5]. The higher the NNTB value, the less effective the treatment 19 
will be; and, the higher the NNTH, the more safe a treatment is. For example, intervention 20 
A with a NNTB of 20 whereby one patient is saved for every 20 patients treated with A is 21 
better than a competing intervention B (with a NNTB of 80) that saves one patient for 22 
every 80 patients treated with B. The use and interpretation of NNT requires understanding 23 
of several factors [1, 6], such as: 1) clinical insight and patient values and circumstances, 24 
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as it may depend on how difficult it is to implement the intervention and how accessible 25 
and cost-effective the intervention is, 2) follow-up period, as NNTs in studies with 26 
different follow-up times are not directly comparable [7], 3) baseline risk of the event, 4) 27 
statistical properties of NNT, 5) alternative treatment to which the intervention is being 28 
compared, 6) outcome, 7) direction and size of the effect measure, 8) NNTB (and NNTH) 29 
scale, and 9) confidence interval (CI) surrounding NNTB or NNTH [4, 8]. CIs for NNTs 30 
can be calculated to inform us about the range of NNT values we may expect. However, 31 
CIs for the estimated NNTs are usually given for statistically significant results [8], and 32 
this is mainly due to a complication of the NNT calculation when dealing with non-33 
significant results (i.e., there is discontinuity when RD is 0).  34 
The NNT measure has been particularly useful in systematic reviews and meta-35 
analyses [3]. However, caution is needed in the NNT calculation as differences in baseline 36 
risks, lengths of follow-up, outcome definitions, and clinical settings across the studies 37 
included in a meta-analysis can impact the magnitude and direction of NNT [1]. In the 38 
meta-analysis context, it is recommended to calculate NNT using an overall treatment 39 
effect that remains constant in baseline risk variations. For example, is has been shown that 40 
OR and RR effect measures appear to be relatively constant for differences in  across 41 
studies [9]. Caution is also needed when the between-study heterogeneity in the included 42 
studies’ results is substantial. When the study-specific effect measures vary substantially 43 
(e.g., due to notable differences in baseline risks or in patient characteristics or in study-44 
designs), it may not be advisable to combine the study results into a single overall effect 45 
estimate or calculate the respective NNT. 46 
Overall, the NNT is a clinically useful measure for expressing binary and survival 47 
outcome results [10], and is frequently used in the published literature [11-13]. Several 48 
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attempts have also been made to extend NNT for continuous outcomes [14, 15], as well as 49 
to graphically represent NNTs [4, 16, 17]. However, knowledge users (such as patients, 50 
healthcare providers, and policy-makers) are faced with a multitude of intervention options 51 
and the need to compare several treatments for a clinical condition are required to make 52 
informed health-care decisions. As such, more complex statistical approaches, such as 53 
network meta-analysis (NMA) are required. NMA combines the results of trials that 54 
undertake different treatment comparisons [18-20] and is being conducted with increasing 55 
frequency in the healthcare literature [21, 22]. The aim of this paper is to present graphical 56 
approaches of NNTs from NMA to facilitate interpretation of results.  57 
2. Number needed to treat in pairwise and network meta-analysis 58 
A NNT can be calculated from the overall RD, RR, and OR effect measures using 59 
the following formulas: 60 
NNT = 1/|RD| 
NNT =
1
(1 − RR) ∙ 
 
NNT =
1 −  + OR ∙ 
(1 − OR) ∙  ∙ (1 − )
 
where  is the control (or placebo or usual care) event rate, defined as the observed risk 61 
of having an event in the control group (ranges between 0 and 1). A barrier to expanding 62 
the use of NNT in meta-analysis when an OR or RR is used, is the determination of a 63 
single  value, as the  will vary for each study included in the meta-analysis. 64 
Below we present potential ways of analyzing  in meta-analysis: 65 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
9 
 
1. The naïve approach, where the sum of events in the control group is divided by the 66 
sum of patients in the control group. 67 
2. Median/Mean  across all studies containing the control group 68 
3. Pooled  from a meta-analysis across all studies containing the control group 69 
4. Expert opinion based, for example, on the patient population included across the 70 
studies or on local data from the researcher’s own patient population 71 
5. A range of possible  values, which can be used to compare potential NNT 72 
differences. 73 
Of all approaches, the naïve should be avoided, as it ignores study randomization and 74 
between-study variability. To derive a pooled  across studies in a meta-analysis, we 75 
may need to use transformations [23]. The  follows a binomial distribution and its 76 
variance, which is a function of the mean, reaches a maximum value at  = 0.5. While 77 
this works well for  around 0.5, when  is closer to 0 or 1 its variance declines to 0, 78 
and hence an inverse-variance meta-analysis assigns a very large weight to these studies 79 
[23]. Variance-stabilizing transformations help not only to correct this problem in binomial 80 
data, but also to obtain a sampling distribution closer to a normal distribution. Two of the 81 
most common variance-stabilizing transformations are the logit or double arcsine 82 
transformations [23]. While the logit transformation helps better approximate a normal 83 
distribution, the transformed sampling variance can be quite inaccurate. For a  close to 84 
0 or 1 its variance becomes extremely large, while for a  close to 0.5 its variance 85 
becomes extremely low [23]. Hence, an inverse-variance meta-analysis assigns small 86 
weights to studies with small or large  and large weights to  around 0.5, 87 
irrespective of the sample size. To improve normalizing and variance-stabilizing the  88 
sampling distribution, Freeman and Tukey [24] suggested the double arcsine 89 
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transformation. A back-transformation on the original  scale can be performed using 90 
the approach suggested by Miller [25]. However, it has been suggested not to use the 91 
double arcsine transformation for meta-analysis of single proportions due to potential 92 
problems with the back-transformation [26]. As alternative, the application of generalized 93 
linear mixed models is proposed [26]. 94 
Extending the calculation of NNT in NMA, additional considerations to the above 95 
should be made. First, the order of treatments when these are compared in a NMA should 96 
be presented in a meaningful and consistent way, to facilitate the  choice and the NNT 97 
interpretation. A consistent way could be ordering treatments within comparisons referring 98 
to active treatment versus placebo/usual care or referring to new pharmacological treatment 99 
versus old pharmacological treatment (alternative strategies are needed for non-100 
pharmacological interventions). Let us consider the fictional example of 6 studies 101 
comparing treatments A, B, and C, as shown in Appendix 1. If treatment C is newer than 102 
treatment B, which is newer than treatment A, then a presentation of the treatment 103 
comparisons evaluated in the 6 different studies could be B vs. A, B vs. A, B vs. A, C vs. 104 
B, C vs. B, and C vs. A. This facilitates the determination of the comparator (e.g., control) 105 
group in each case, so as to calculate the study-specific . For example, in study 1 that 106 
compares B vs. A a  is defined using evidence from treatment A. A  is defined in 107 
a similar way in studies 2 to 6. Second, a  should be defined across multiple treatment 108 
comparisons that share the same control (or comparator) group. This may include choosing 109 
between a common and comparison-specific . Selection of the most appropriate 110 
assumption will depend on the patient population. However, different assumptions may 111 
impact the NNT results. For example, for an  = 0.80 a common  across all 112 
treatments vs. control and equal to 0.50 gives a NNT = 18, whereas a comparison-specific 113 
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 = 0.05 gives a notably different NNT = 104. In our fictional example in Appendix 1, 114 
a common  across treatment comparisons sharing the same comparator group was 115 
assumed. Hence, the  for treatment A for the treatment comparison B vs. A (. ) 116 
is equal to the . . In particular, under the common  assumption we need to 117 
estimate 2 : . = .  and . . The  for treatment A was 118 
estimated from studies 1, 2, 3 (comparing B vs. A treatments) and 6 (comparing C vs. A 119 
treatments), whereas the  for treatment B was estimated from studies 1, 2, 3 120 
(comparing B vs. A treatments), and 4 and 5 (comparing C vs. B treatments). However, 121 
under the comparison-specific assumption, we need to estimate 3 : . , 122 
.

, and . . In Appendix 1, we used approach 2 and calculated a mean  123 
across studies comparing the same control group. 124 
Once a meaningful  is calculated, the NNT can be determined using the 125 
formulae presented earlier. In Appendix 1, we present NNT using both the OR effect 126 
measure (NNTOR) and the RD (NNTRD) effect measure. To account for uncertainty around 127 
NNT, a CI can be calculated for the NNT values obtained in a NMA. Several approaches 128 
have been suggested to calculate CIs for NNTs for results from RCTs [8, 27], among 129 
which the Daly (or substitution method), the method of variance estimates recovery 130 
(MOVER), and the propagating imprecision (PropImp) CIs can also be used for results 131 
from meta-analyses [28-30]. For the NNT CI calculation, an appropriate method should be 132 
chosen to calculate CIs for the selected effect measure. For a review of methods to obtain 133 
CIs for the estimated overall effect from a random-effects meta-analysis see Veroniki et al. 134 
[31]. If the chosen effect measure is the RD, then the NNT CI is simply obtained by 135 
inverting and exchanging the corresponding RD confidence limits. If the chosen effect 136 
measure is the RR or OR, additionally a meaningful CER is required. The Daly CIs start 137 
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with a CI for the estimated overall treatment effect, and then calculate a CI based on a 138 
transformed scale. Although the method is simple to apply, it does not account for the 139 
estimation uncertainty of , when OR and RR effect sizes are used. On the contrary, the 140 
MOVER and PropImp approaches allow for a degree of imprecision of both treatment 141 
effect and  estimation, and can be used when the estimates of  and treatment 142 
effect are independent (e.g., derived from separate studies). This means that the average 143 
 derived across the same eligible studies should not be used to calculate a MOVER or 144 
PropImp CI for NNT [32]. 145 
In NNT, values between −1 and 1 are impossible, and the domain of NNT uses two 146 
regions: a) the NNTB region, including the union of 1 (where is the largest possible 147 
beneficial treatment effect) to ∞ (no treatment effect), and b) the NNTH region: −∞ (no 148 
treatment effect) to −1 (where is the largest possible harmful treatment effect). For 149 
example, a non-statistically significant NNT=5 with CI −40 and 2 is a combination of the 150 
two regions (−∞,−40] and [2, ∞). The suggested presentation of a non-statistically 151 
significant NNT is: NNTB=5 (NNTH 40 to ∞ to NNTB 2) [4]. The presentation indicates 152 
that a NNTB=5 is estimated implying that on average 5 people should receive the 153 
treatment for an additional beneficial outcome compared to the control group. However, 154 
the uncertainty of this estimation is large with a harmful effect up to NNTH=40, a less 155 
harmful effect up to NNTH =∞ (no effect; need to treat an infinite number of people to 156 
cause or avoid an event), and a more beneficial effect up to NNTB=2. Because of this 157 
limitation and the difficulty in interpreting a non-statistically significant NNT, many 158 
authors do not report a CI for non-statistically significant NNTs. 159 
In Appendix 1 we present a 95% CI for each NNT using the Daly approach [30]. It 160 
should be highlighted that the resulting CIs for NNTOR contain only the OR uncertainty 161 
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and do not account for  uncertainty. Hence, the NNT estimation is conditional on the 162 
assumed . However, in case of large between-study heterogeneity, we recommend the 163 
use of various clinically meaningful  values (e.g. for low- and high-risk patients) to 164 
explore differences in NNT. In case a  estimate with CI is available, which is 165 
independent of the (network) meta-analysis, the PropImp approach can be used to calculate 166 
CIs for NNTs taking into account uncertainty of the  and the OR estimation [29]. In  167 
Appendix 1,  the NNT values slightly differ when calculated from OR and from RD.  This 168 
is because different properties are associated with different effect measures, which can 169 
affect the NNT value. It should also be considered that small changes in RD close to zero 170 
may result in large changes in the estimation of NNT, as RD = 0 corresponds to NNT =171 
±∞172 
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3. Illustrative Example 173 
To illustrate different approaches for the graphical representation of NNT (see 174 
section 4) we use a published systematic review and NMA on the comparative 175 
effectiveness and safety of cognitive enhancers for treating Alzheimer’s dementia [33]. 176 
The example includes eight dichotomous outcomes and 10 treatments. The network 177 
representation of each outcome is presented in Appendix 2. The treatment comparisons 178 
including placebo, the estimated ORs, RRs, and RDs in a frequentist NMA (using the 179 
mvmeta command is Stata) [34], the mean , and the estimated NNTs for each 180 
outcome and effect measure are provided in Appendix 3. In this example, we used the OR, 181 
which was transformed to NNT for the graphical approaches in section 4. To ease 182 
interpretation in plots, we present the results on the RD scale after converting the 183 
transformed NNTs to RDs. For illustration purposes, we also present in Appendices 4-10 184 
the same graphical approaches using the RD effect measure as estimated in NMA and its 185 
convertion to the NNT scale. However, it should be noted that the use of the RD effect 186 
measure is not appropriate in this example. Nevertheless, we used this approach here to 187 
illustrate the different graphs for RD-based NNTs without switching to another data 188 
example. We ordered treatments from oldest to newest by year of availability in 189 
Canada[33], used approach 2 and calculated a mean  across studies comparing the 190 
control group, and considered a common  value across treatment comparisons 191 
including the same, older treatment. Since the aim of this paper is to present different ways 192 
of depicting NNT, we used a single  value to calculate NNT under the OR (and RR in 193 
Cates plot in Appendix 5) effect measure. We calculated a 95% CI for each NNT using the 194 
Daly approach [30]. In the following, we infer on whether a treatment is harmful or 195 
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beneficial based on the NNT scale, i.e. a treatment is harmful when NNTH ranges between 196 
1 and ∞, and a treatment is beneficial when NNTB ranges between 1 and ∞. 197 
4. Graphical approaches for NNT based on absolute measures 198 
Several graphical ways can be used to present the NNT in a NMA. In this paper, we 199 
discuss six potential approaches to graphically represent NNT. We also categorize the plots 200 
when a single outcome or multiple outcomes are available in a NMA. The uncertainty 201 
around NNT can graphically be depicted in a bar plot and a forest plot. A scatterplot can 202 
also be extended to include CIs for NNTs as ellipse regions across treatment comparisons 203 
and outcomes [35]. For a comparison of the graphical approaches see Appendix 11. 204 
4.1 Plots for a single outcome 205 
4.1.1 Bar plot  206 
A bar plot can graphically depict the NNT for each treatment comparison or the 207 
NNT for the treatments compared to a common comparator (e.g., placebo), as presented in 208 
Figure 1.  209 
In Figure 1, we graphically represent the NNT values of 6 treatments for 210 
Alzheimer’s dementia vs. placebo for the vomiting outcome [33] of 42 RCTs and 12,997 211 
patients, in a bar plot. According to the NNT point estimates, all treatments but one are 212 
suggested as harmful treatments compared to placebo. The only beneficial treatment is 213 
memantine (NNTB=27, 95% CI [NNTH 3, ∞, NNTB 15]), suggesting that 27 patients need 214 
to be treated with memantine compared to placebo to prevent one patient from vomiting. 215 
However, the point estimate is associated with large uncertainty, where its CI goes from 216 
large harm to large benefit. Donepezil, galamantine, and oral rivastigmine are statistically 217 
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significantly more harmful against placebo. The most harmful treatment among the 6 218 
treatments evaluated in a NMA vs. placebo is oral rivastigmine (NNTH=7, 95% CI [5,14]), 219 
suggesting that 7 patients need to be treated with oral rivastigmine in order for one patient 220 
to vomit. 221 
(Figure 1 here) 222 
4.1.2 Cates plot 223 
A Cates plot can be used to graphically present the NNT values derived from NMA 224 
evidence. The Cates plot shows the average rate of having a good outcome with treatment 225 
(green faces), a bad outcome with treatment (red faces), a better outcome with control 226 
(crossed green faces), and a change in outcome category if a patient is treated (yellow 227 
faces) per treatment comparison. 100 faces are depicted in a Cates plot representing 228 
patients treated with the underlying treatment. The more green faces in a section referring 229 
to a certain treatment comparison indicate the most beneficial the treatment against its 230 
comparator, whereas the more red faces in a section referring to a certain treatment 231 
comparison indicate the most harmful the treatment against its comparator. 232 
Assuming a common  across comparisons with mean  = 7% across 233 
studies, we plotted a Cates plot for each treatment against placebo at 234 
http://www.nntonline.net/visualrx/. Figure 2 demonstrates the Cates plot for the vomiting 235 
outcome and 6 treatments against placebo: donepezil, galantamine, oral rivastigmine, 236 
transdermal patch rivastigmine, memantine, and rivastigmine + memantine. This plot 237 
suggests that the most beneficial treatment is memantine, where 93 patients treated with 238 
memantine had a good outcome of not vomiting, 4 patients, who would vomit without 239 
memantine, had a change in outcome and did not vomit after receiving treatment, and 3 240 
patients had a bad outcome of vomiting even if they were treated with memantine 241 
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(NNTB=27, 95% CI [NNTH 3, ∞, NNTB 15]). The least harmful treatment is transdermal 242 
patch rivastigmine, where 38 patients need to be treated with transdermal patch 243 
rivastigmine in order for one patient to vomit (NNTH=37, 95% CI [NNTH 8, ∞, NNTB 244 
39]). The Cates plot suggests that 90 patients treated with transdermal patch rivastigmine 245 
had a good outcome of not vomiting, 3 patients had an adverse event with transdermal 246 
patch rivastigmine and their category from a good outcome changed to a bad outcome of 247 
vomiting, and 7 patients had a bad outcome of vomiting even if they were treated with 248 
transdermal patch rivastigmine. 249 
(Figure 2 here) 250 
4.1.3 Forest plot 251 
A forest plot can graphically depict the estimated NNT for each treatment 252 
comparison. On the x-axis the RD × 100% scale is shown with 0% corresponding to the 253 
line of no treatment difference, and on the y-axis the treatment comparisons are presented. 254 
The NNT values along with their CIs are depicted on the left hand-side of the plot next to 255 
the RD values. In the forest plot, each treatment comparison is presented by a diamond on 256 
the RD × 100% scale and a horizontal line extending either side of the diamond depicts a 257 
CI for RD × 100%. The treatment comparisons may be divided into subsets for 258 
presentation in a forest plot, such as according to the common comparator in the NMA 259 
treatment comparisons.  260 
The forest plot of 6 treatments against placebo assessed for vomiting in a NMA of 261 
patients with Alzheimer’s dementia is shown in Figure 3. This plot shows that donepezil, 262 
galantamine, and oral rivastigmine are statistically significantly harmful when compared 263 
with placebo, and among the three treatments the highest uncertainty around NNT is 264 
observed for donepezil (NNTH=22, 95% CI [10,113]). Memantine, transdermal patch 265 
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rivastigmine, and rivastigmine + memantine are associated with non-statistically 266 
significant NNTs and very wide 95% CIs. 267 
(Figure 3 here) 268 
4.2 Plots for multiple outcomes 269 
4.2.1 Bubble plot 270 
A bubble plot shows the NNT values for all treatment comparisons assessed in a 271 
NMA for two outcomes. The plot arranges the presentation of NNT for all treatments on a 272 
certain outcome on the x-axis against the treatments included in a second outcome on the 273 
y-axis. Let us define that the outcome presented at the lower diagonal part of the plot is 274 
outcome 1 (e.g., headache in Figure 4) and the outcome presented at the upper diagonal 275 
part of the plot is outcome 2 (e.g., nausea in Figure 4). The direction of the treatment 276 
comparisons in outcome 1 (e.g., headache) is defined as treatment at the relevant row (e.g., 277 
donepezil) vs. treatment at the relevant column (e.g., placebo). Similarly, the direction of 278 
the treatment comparisons in outcome 2 (e.g., nausea) is defined as treatment at the 279 
relevant row (e.g., placebo) vs. treatment at the relevant column (e.g., donepezil). The 280 
diagonal of the plot gives no information about NNT. The area in each circle is 281 
proportional to the absolute RD × 100%, and the number in each circle represents the NNT 282 
value for the corresponding treatment against the comparator for the specific outcome. 283 
However, a challenge with bubble plots is that the smaller the circle, the harder it is to read 284 
the NNT value. Each point corresponds to four pieces of information: treatment 285 
comparison, magnitude of RD, benefit/harm of treatment, and NNT value. Green circles 286 
represent the number of patients need to be treated to prevent one patient from having an 287 
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event, whereas red circles show the number of patients need to be treated in order for one 288 
patient to experience a harmful event.  289 
Figure 4 demonstrates the bubble plot for the NNT of 8 NMA treatments included 290 
in headache (x-axis) and nausea (y-axis) outcomes. In this plot, the NNT values for all 291 
NMA treatment comparisons are presented according to headache (lower diagonal) and 292 
nausea (upper diagonal) outcomes. For example, for the headache outcome, the 293 
comparison row treatment vs. column treatment donepezil vs. placebo has a NNTH=73, 294 
whereas in nausea the comparison row treatment vs. column treatment placebo vs. 295 
donepezil has a NNTB=17 (equivalent to donepezil vs. placebo: NNTH=17). The plot 296 
suggests that the most beneficial treatment for nausea is donepezil + memantine against 297 
placebo (donepezil + memantine vs. placebo: NNTB=17), but the same treatment is the 298 
most harmful treatment for headache against placebo (donepezil + memantine vs. placebo: 299 
NNTH=7). The only beneficial treatment against placebo in headache is rivastigmine + 300 
memantine, which is also beneficial in nausea (rivastigmine + memantine vs. placebo, 301 
headache: NNTB=33, nausea: NNTB=55). The least beneficial treatment in nausea is 302 
transdermal patch rivastigmine, which is one of the most harmful treatments against 303 
placebo in headache (transdermal patch rivastigmine vs. placebo, headache: NNTH=17, 304 
nausea: NNTB=117). 305 
(Figure 4 here) 306 
4.2.2 Scatterplot 307 
For the case of two outcomes, two-dimensional scatterplots can be used, which can 308 
be extended to the case of three outcomes with three-dimensional plots. The plot presents 309 
both the RD × 100% and NNT values for treatments against a common comparator across 310 
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two (or a maximum of three) outcomes. Clustering methods can be used to group the NNT 311 
performance of treatments according to their efficacy and/or safety [36]. 312 
Figure 5 depicts the RD × 100% values of 7 treatments against placebo for 313 
headache and nausea in a scatterplot. The NNT scale is presented on the right and upper 314 
scales of the plot. The plot suggests that the only beneficial treatment vs. placebo in both 315 
outcomes is rivastigmine + memantine (headache: NNTB=33, nausea: NNTB=55). The 316 
least beneficial treatment in nausea is transdermal patch rivastigmine against placebo 317 
(NNTB=117), whereas the only beneficial treatment in headache is rivastigmine + 318 
memantine. The most harmful treatment in the headache outcome is donepezil + 319 
memantine vs. placebo (NNTH=7), but the same treatment is the most beneficial treatment 320 
in the nausea outcome vs. placebo (NNTB=17). 321 
 (Figure 5 here) 322 
4.2.3 Rank-heat plot 323 
The rank-heat plot can be used for the visual presentation of the NNT values across 324 
multiple treatments and outcomes [37]. A rank-heat plot includes N circles with the same 325 
center corresponding to the N outcomes assessed in a NMA. The radii included in each 326 
concentric circle correspond to T treatment comparisons as assessed in NMA. Instead of 327 
presenting all available treatment comparisons, one can present the NMA treatments 328 
against a common comparator (e.g., placebo). Each section in the rank-heat plot is colored 329 
according to the NNT value of the particular treatment at the corresponding outcome. The 330 
NNT scale ranges from NNTH=1 to ∞ to NNTB=1 and is transformed using three colors: 331 
red (NNTH=1) yellow (NNTH/NNTB=∞) and green (NNTB=1). Although the color of the 332 
section is interpretable, the section area does not convey any information. Statistically 333 
significant NNT results are depicted in the rank-heat plot by highlighting the borders in the 334 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
21 
 
corresponding section. Uncolored sections refer to NMA treatments without data on the 335 
outcome within the circle. A star symbol can be used to highlight these cases (see 336 
https://rh.ktss.ca/site/nnt). 337 
Figure 6 displays the hierarchy of 10 treatments for Alzheimer’s dementia against 338 
placebo across 8 outcomes according to their NNT values in a rank-heat plot. The NNT 339 
scale is presented at the top of the graph. The plot suggests that donepezil + memantine lies 340 
among the most beneficial treatments when compared with placebo across most outcomes 341 
except for headache with NNTH=7. However, due to lack of evidence we cannot infer the 342 
treatment’s harm or benefit in bradycardia and diarrhea outcomes. Across all outcomes and 343 
treatment comparisons, 10 NNTs are statistically significant and these refer to donepezil, 344 
galamantine, and oral rivastigmine treatments. 345 
 (Figure 6 here) 346 
All plots can present NNTs from NMA, but the bar plot, Cates plot, and forest plot 347 
can be cumbersome when a large number of NNTs is available, especially when more than 348 
one outcome is available. An NNT can be particularly helpful when different outcomes 349 
with widely different  values (e.g., harmful and beneficial outcomes) are compared, to 350 
reflect the different likelihood of each outcome. Similarly, an NNT is helpful for 351 
comparing different interventions. A disadvantage of the bubble plot is that the smaller the 352 
circle the harder it is to read the NNT value, whereas a scatterplot cannot be produced 353 
when different treatments (or treatment comparisons) are included in the studied outcomes. 354 
A challenge associated with the Cates plot, bubble plot, and rank-heat plot is that they do 355 
not depict the NNT uncertainty, which can impact interpretation. Although the 356 
interpretation of non-statistically significant NNTs is challenging, when we only consider a 357 
NNT point estimate or direction of effect that shows benefit (or harm) and do not account 358 
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for the huge estimation uncertainty (CI is going from large harm to large benefit), our 359 
conclusions can be misleading. For example, based on the NNT point estimate 360 
rivastigmine + memantine is suggested as a beneficial treatment when compared to placebo 361 
in both headache and nausea outcomes (headache: NNTB=33, nausea: NNTB=55). 362 
Interpreting only the point estimates rather than the combination of point estimates and 363 
uncertainty around them can lead to an erroneous decision making considering also that 364 
nausea and headache are adverse events related to these medications (headache: NNTB 33 365 
(NNTH 2, ∞, NNTB 13), nausea: NNTB 55 (NNTH 7, ∞, NNTB 15)). The Forest plot on 366 
the RD scale is probably one of the easiest ways to present uncertainty around each result, 367 
followed by the bar plot.  368 
5. Discussion 369 
We recommend the presentation of NNT along with the relevant effect measure and 370 
its CI when it is useful to describe the treatment effects in an absolute scale. The NNT 371 
values can be presented for all available or selected treatment comparisons (e.g., active 372 
treatments vs. placebo) from a NMA. We suggest the presentation of all results using the 373 
main effect measure used in the analysis (e.g., OR), and of selected, interesting for the 374 
considered research question, results using NNT. An important consideration when 375 
calculating NNT, is that it may vary according to the effect measure used in meta-analysis 376 
or NMA. Therefore, it is important to choose the appropriate main effect measure in meta-377 
analysis or NMA before NNTs are calculated.  378 
When the OR or RR effect measures are used in meta-analysis or NMA, a useful 379 
 should be assumed to estimate NNT. As discussed in section 2, several ways exist to 380 
select a  value for the NNT calculation, including mean  across studies, pooled 381 
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 in meta-analysis, expert opinion-based , and range of possible . In the 382 
presence of small to moderate heterogeneity, we suggest the use of several  values 383 
(e.g. for low- and high-risk patients) to estimate a NNT and assess robustness of results. By 384 
means of these assumed  we can calculate NNTs and their CIs (e.g., based upon the 385 
Daly approach [30], but this neglects the estimation uncertainty of ). In case external 386 
estimation of  is available (e.g., from registry data), which is independent on the data 387 
used in the underlying meta-analysis or NMA, and in case the RR is the main effect 388 
measure, we can use the MOVER approach to estimate NNT and its CI taking into account 389 
the  estimation uncertainty [28]. In case the OR is the main effect measure, the 390 
PropImp approach can be used [29]. In NMA, additional considerations are required to 391 
calculate NNTs, which include a meaningful and consistent order of treatments to facilitate 392 
the  choice for NNT calculation and interpretation, and a selection among different 393 
 assumptions (i.e., common or comparison-specific ). Since NNT is dependent on 394 
 and study duration, the comparison of multiple treatments for a specific outcome 395 
through NNT may be difficult. The selection among different  assumptions depends 396 
on the clinical field and the nature of the treatments assessed in an NMA. If different  397 
values (e.g., derived from control arms of the included studies) influence the NNT 398 
calculation, then this should be considered when interpreting the NNT. We suggest that 399 
NNTs always be interpreted along with the relevant treatment effects and their confidence 400 
intervals estimated in a meta-analysis or NMA. Ranking statistics derived from an NMA 401 
model can also be used as complementary information to NNTs to compare treatments 402 
within each outcome of interest [38]. 403 
In this paper, we discussed the NNT calculation for dichotomous data. However, 404 
the estimation of NNT can also be helpful for continuous outcomes. A way to calculate 405 
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NNT for continuous data can be by converting a standardized mean difference to OR and 406 
then calculate NNT [5] or by dichotomizing the continuous data and then calculate an 407 
effect size for dichotomous data. In any case, we suggest to graphically represent NNT to 408 
ease interpretation. However, it should be considered that the NNT interpretation may 409 
differ according to the NMA considerations, including selection of effect size and , as 410 
well as  assumption across multiple comparisons. 411 
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Figure Legend 
Figure 1. Bar plot of 6 treatments against placebo for the vomiting outcome. On the x-axis, the treatment 
comparisons are presented, and on the y-axis, the RD×100% scale is shown, whereas the NNT values along 
with their CIs are depicted at the top of each bar. Each vertical bar depicts the RD×100% value that 
corresponds to the specific treatment comparison, and each vertical line crossing a bar correspond to the error 
bars depicting the 95% CI for RD×100%. Error bars crossing the line of no effect (RD×100%=0%) suggest a 
non-statistically significant result.The greater the area in a bar, the larger the absolute RD, i.e., the smaller the 
NNTB (or NNTH) value, and hence the most beneficial (or harmful) the treatment. We can distinguish 
between harmful (below the horizontal line of no effect) and beneficial (above the horizontal line of no 
effect) treatments using red and green colored bars, respectively. On the horizontal axis the 6 treatment 
comparisons are presented, whereas on the vertical axis the RD×100% value of each treatment comparison is 
presented. Each bar represents one of the 6 (i.e., total number of treatments in vomiting outcome-1) possible 
comparisons against a common comparator (i.e., placebo). The error bars represent the 95% CI for NNT. 
Green bars represent the number of patients need to be treated to prevent one patient from experiencing the 
event; red bars represent the number of patients need to be treated in order for one patient to experience the 
event. Although the NNT scale suggests that memantine is the only beneficial treatment compared to its 
alternatives in the network, given that memantine does not treat vomiting clinically memantine would be 
described as the least harmful treatment.  
Abbreviations: CI, confidence interval; DONE, donepezil; GALA, galantamine; MEMA, memantine; NNT, 
number needed to treat; NNTB, number needed to treat for an additional beneficial outcome; NNTH, number 
needed to treat for an additional harmful outcome; RD, risk difference; RIVA, rivastigmine; RIVA_O, oral 
rivastigmine; RIVA_P, transdermal patch rivastigmine. 
 
Figure 2. Cates plot representing 6 treatments against placebo in the vomiting network. Each region 
corresponds to a different treatment (vs. placebo) and includes 100 faces corresponding to the patients treated 
with the underlying treatment. Green faces represent patients not vomiting with the underlying treatment; red 
faces represent patients vomiting with the underlying treatment; crossed green faces represent patients not 
vomiting with control; yellow faces represent patients that would not vomit if they would be treated with the 
underlying treatment. The NNT values have been re-calculated in http://www.nntonline.net/visualrx/ using 
the odds ratios estimated in a NMA model and a mean CER=7%. Although the NNT scale suggests that 
memantine is the only beneficial treatment compared to its alternatives in the network, given that memantine 
does not treat vomiting clinically memantine would be described as the least harmful treatment.  
Abbreviations: CER, control event rate; NMA, network meta-analysis; NNT, number needed to treat; NNTB, 
number needed to treat for an additional beneficial outcome; NNTH, number needed to treat for an additional 
harmful outcome. 
 
Figure 3. Forest plot for 6 NMA treatment comparisons against placebo to assess vomiting in Alzheimer’s 
dementia. The RD×100%, its 95% CI, the corresponding NNT and its 95% CI for each comparison are 
shown. Note that the pooled or effect measure estimated in NMA has been transformed to NNT, and the 
NNT has been converted to an RD effect measure, which is presented in this plot.  
Abbreviations: CI, confidence interval; NNT, number needed to treat; NNTB, number needed to treat for an 
additional beneficial outcome; NNTH, number needed to treat for an additional harmful outcome; RD, risk 
difference. 
 
Figure 4. Bubble plot for the 8 NMA treatments (including placebo) included in headache (x-axis) and 
nausea (y-axis) outcomes. The NNT values for each pair of the Alzheimer’s dementia treatments according to 
headache (lower diagonal) and nausea (upper diagonal) are presented. The area of each circle is proportional 
to the RD×100% value of each treatment comparison, and the NNT value is presented in the center of each 
circle. Green circles represent the number of patients need to be treated to prevent one patient from 
experiencing the event; red circles represent the number of patients need to be treated in order for one patient 
to experience the event. The direction of the treatment comparisons is defined as row treatment vs. column 
treatment. Although the NNT scale suggests that there are beneficial treatments in the network, given that 
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these treatments do not treat nausea or headache clinically they would be described as the less harmful 
treatments.  
Abbreviations: DONE, donepezil; GALA, galantamine; MEMA, memantine; NMA, network meta-analysis; 
NNT, number needed to treat; NNTB, number needed to treat for an additional beneficial outcome; NNTH, 
number needed to treat for an additional harmful outcome;  PLAC, placebo; RD, risk difference;  RIVA, 
rivastigmine; RIVA_O, oral rivastigmine; RIVA_P, transdermal patch rivastigmine. 
 
Figure 5. Scatterplot for the NNT of 7 treatments vs. placebo for headache (x-axis) and nausea (y-axis) 
outcomes for patients with Alzheimer’s dementia. Treatments lying on the upper right hand side quarter are 
more beneficial against placebo for both outcomes. Although the NNT scale suggests that there are beneficial 
treatments in the network, given that these treatments do not treat nausea or headache clinically they would 
be described as the less harmful treatments.  
Abbreviations: DONE, donepezil; GALA, galantamine; MEMA, memantine; NNT; number needed to treat; 
RIVA, rivastigmine; RIVA_O, oral rivastigmine; RIVA_P, transdermal patch rivastigmine. 
 
Figure 6. Rank-heat plot of the NNT values of 8 treatments in 8 different outcomes. Each section is colored 
according to the NNT value of the corresponding treatment and outcome. The scale consists of the 
transformation of three colors red (NNTH=1), yellow (∞), and green (NNTB=1). Each section includes also 
the NNT value corresponding to the specific treatment and outcome. Highlighted borders in a section 
correspond to statistically significant NNT results. Uncolored sections show that the underlying treatment 
was not included in the NMA for the particular outcome. Although the NNT scale suggests that there are 
beneficial treatments in the network, given that these treatments do not treat nausea or headache clinically 
they would be described as the less harmful treatments.  
Abbreviations: DONE, donepezil; GALA, galantamine; MEMA, memantine; NMA, network meta-analysis; 
NNT, number needed to treat; NNTB, number needed to treat for an additional beneficial outcome; NNTH, 
number needed to treat for an additional harmful outcome; RIVA, rivastigmine; RIVA_O, oral rivastigmine; 
RIVA_P, transdermal patch rivastigmine; SAE, serious adverse events.  
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Additional Files 
File name: Supplementary File 
Appendix 1: Table for fictional example for the calculation of NNT in NMA.  
Fictional example for the calculation of NNT in NMA. For each treatment comparison a 
pooled OR and a pooled RD was calculated in a random-effects NMA model using the 
mvmeta command in Stata [34]. A study-specific CER was calculated for treat2 (even if 
this was not the reference/control group) across treatment comparisons. A common CER 
across treatment comparisons sharing the same comparator (e.g., control) group was 
assumed. The CER for treatment A was estimated from studies 1, 2, 3, and 6; the CER for 
treatment B was estimated from studies 1, 2, 3, 4, and 5. A mean CER was calculated 
across studies, and a 95% CI for NNT across treatment comparisons was calculated using 
the Daly approach. 
Abbreviations: CER, control event rate; CI, confidence interval; Comp, comparison; N, 
sample size; NMA, network meta-analysis; NNT, number needed to treat; NNTB, number 
needed to treat for an additional beneficial outcome; NNTH, number needed to treat for an 
additional harmful outcome; OR, odds ratio; RD, risk difference; Treat, treatment 
 
Appendix 2: Network representation of eight outcomes included in the illustrative 
example [33]   
Each treatment node is proportional to the number of patients in the particular treatment, 
and each edge is proportional to the number of studies comparing the treatments it 
connects.  
Abbreviations: DONE, donepezil; GALA, galantamine; MEMA, memantine; PLAC, 
placebo; RIVA, rivastigmine; RIVA_O, oral rivastigmine; RIVA_P, transdermal 
rivastigmine; SAE, serious adverse events 
 
Appendix 3. NNT values across all treatments vs. placebo in 8 Alzheimer’s dementia 
outcomes.  
Treatment comparisons including placebo, estimated odds ratios (ORs), risk ratios (RRs), 
and risk differences (RDs), mean control event rates (CER), and estimated number needed 
to treat (NNT) for each outcome in the Alzheimer’s dementia dataset [33] and effect 
measure. All effect measures were calculated in a frequentist network meta-analysis using 
the mvmeta Stata [34] routine. 
Abbreviations: CER, control event rate; CI, confidence interval; CrI, credible interval; 
DONE, donepezil; GALA, galantamine; MEMA, memantine; N, sample size; NMA, 
network meta-analysis; NNT, number needed to treat; NNTB, number needed to treat for 
an additional beneficial outcome; NNTH, number needed to treat for an additional harmful 
outcome; OR, odds ratio; PLAC, placebo; RD, risk difference; RIVA, rivastigmine; 
RIVA_O, oral rivastigmine; RIVA_P, transdermal patch rivastigmine; RR, risk ratio; 
Treat, treatment; SAE, serious adverse events 
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Appendix 4. Bar plot of NNT values across 6 treatments vs. placebo in vomiting 
outcome.  
Bar plot of 6 treatments against placebo for the vomiting outcome. On the horizontal axis 
the 6 treatment comparisons are presented, whereas on the vertical axis the RD×100% 
value of each treatment comparison is presented. Each bar represents one of the 6 (i.e., 
total number of treatments in vomiting outcome-1) possible comparisons against a 
common comparator (i.e., placebo). The error bars represent the 95% CI for NNT. Green 
bars represent the number of patients need to be treated to prevent one patient from 
experiencing the event; red bars represent the number of patients need to be treated in order 
for one patient to experience the event. NNT values have been calculated from pooled RD 
effect sizes estimated in NMA. Positive RD values correspond to NNTH values, since the 
outcome is harmful.   
Abbreviations: DONE, donepezil; GALA, galantamine; MEMA, memantine; NNTB, 
number needed to treat for an additional beneficial outcome; NNTH, number needed to 
treat for an additional harmful outcome; RIVA, rivastigmine; RIVA_O, oral rivastigmine; 
RIVA_P, transdermal patch rivastigmine 
 
Appendix 5. Cates plot of NNT values across 6 treatments vs. placebo in vomiting 
outcome.  
Cates plot representing 6 treatments against placebo in the vomiting network. Each region 
corresponds to a different treatment (vs. placebo) and includes 100 faces corresponding to 
the patients treated with the underlying treatment. Green faces represent patients not 
vomiting with the underlying treatment; red faces represent patients vomiting with the 
underlying treatment; crossed green faces represent patients not vomiting with control; 
yellow faces represent patients that would not vomit if they would be treated with the 
underlying treatment. The NNT values have been re-calculated in 
http://www.nntonline.net/visualrx/ using the risk ratios estimated in a NMA model and a 
mean CER=6.92%.  
Abbreviations: DONE, donepezil; GALA, galantamine; MEMA, memantine; NMA, 
network meta-analysis; NNTB, number needed to treat for an additional beneficial 
outcome; NNTH, number needed to treat for an additional harmful outcome; RIVA, 
rivastigmine; RIVA_O, oral rivastigmine; RIVA_P, transdermal patch rivastigmine 
 
Appendix 6. Forest plot of NNT values across 6 treatments vs. placebo in vomiting 
outcome.  
Forest plot for 6 NMA treatment comparisons against placebo to assess vomiting in 
Alzheimer’s dementia. The RD×100%, its 95% CI, the corresponding NNT and its 95% CI 
for each comparison are shown NNT values have been calculated from pooled RD effect 
sizes estimated in NMA. Positive RD values correspond to NNTH values, since the 
outcome is harmful. 
Abbreviations: CI, confidence interval; DONE, donepezil; GALA, galantamine; MEMA, 
memantine; NMA, network meta-analysis; NNTB, number needed to treat for an additional 
beneficial outcome; NNTH, number needed to treat for an additional harmful outcome; 
RIVA, rivastigmine; RIVA_O, oral rivastigmine; RIVA_P, transdermal patch rivastigmine 
 
Appendix 7. Bubble plot of NNT values across all treatment comparisons among 8 
treatments (including placebo) assessed in headache and nausea outcomes.  
Bubble plot of NNT values across all treatment comparisons among 8 treatments 
(including placebo) assessed in headache (x-axis) and nausea (y-axis) outcomes. The NNT 
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values for each pair of the Alzheimer’s dementia treatments according to headache (lower 
diagonal) and nausea (upper diagonal) are presented. The area of each circle is proportional 
to the RD×100% value of each treatment comparison, and the NNT value is presented in 
the centre of each circle. Green circles represent the number of patients need to be treated 
to prevent one patient from experiencing the event; red circles represent the number of 
patients need to be treated in order for one patient to experience the event. The direction of 
the treatment comparisons is defined as row treatment vs. column treatment. NNT values 
have been calculated from pooled RD effect sizes estimated in NMA. Positive RD values 
correspond to NNTH values, since the outcomes are harmful. 
Abbreviations: DONE, donepezil; GALA, galantamine; MEMA, memantine; RIVA, 
rivastigmine; RIVA_O, oral rivastigmine; RIVA_P, transdermal patch rivastigmine 
 
Appendix 8. Scatterplot of NNT values across 7 treatments vs. placebo in headache 
and nausea outcomes.  
Scatterplot for the NNT of 7 treatments vs. placebo for headache (x-axis) and nausea (y-
axis) outcomes for patients with Alzheimer’s dementia. Treatments lying on the upper 
right-hand side quarter are more harmful against placebo for both outcomes. In this 
example all treatments lie on the upper right hand side quarter, since all are more harmful 
than placebo. NNT values have been calculated from pooled RD effect sizes estimated in 
NMA. Positive RD values correspond to NNTH values, since the outcomes are harmful. 
Abbreviations: DONE, donepezil; GALA, galantamine; MEMA, memantine; NNTB, 
number needed to treat for an additional beneficial outcome; NNTH, number needed to 
treat for an additional harmful outcome; RIVA, rivastigmine; RIVA_O, oral rivastigmine; 
RIVA_P, transdermal patch rivastigmine 
 
Appendix 9. Rank-heat plot of NNT values across all treatment comparisons among 8 
treatments (including placebo) assessed in 8 Alzheimer’s dementia outcomes.  
Rank-heat plot of the NNT values across all treatment comparisons among 8 treatments 
(including placebo) assessed in 8 different outcomes. Each section is coloured according to 
the NNT value of the corresponding treatment and outcome. The scale consists of the 
transformation of three colours red (NNTH=1), yellow (∞), and green (NNTB=1). Each 
section includes also the NNT value corresponding to the specific treatment and outcome. 
Highlighted borders in a section correspond to statistically significant NNT results. 
Uncoloured sections show that the underlying treatment was not included in the NMA for 
the particular outcome. NNT values have been calculated from pooled RD effect sizes 
estimated in NMA. 
Abbreviations: DONE, donepezil; GALA, galantamine; MEMA, memantine; NMA, 
network meta-analysis; NNT, number needed to treat; NNTB, number needed to treat for 
an additional beneficial outcome; NNTH, number needed to treat for an additional harmful 
outcome; PLAC, placebo; RD, risk difference; RIVA, rivastigmine; RIVA_O, oral 
rivastigmine; RIVA_P, transdermal patch rivastigmine; SAE, serious adverse events 
 
Appendix 10. Interval plot of NNT values across 6 treatments vs. placebo in vomiting 
outcome.  
Interval plot for 6 NMA treatment comparisons against placebo to assess vomiting in 
Alzheimer’s dementia. The x-axis represents the treatment comparisons and the y-axis 
depicts the RD×100% scale. The RD×100%, its 95% CI, the corresponding NNT and its 
95% CI for each comparison are shown. NNT values have been calculated from pooled RD 
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effect sizes estimated in NMA. Positive RD values correspond to NNTH values, since the 
outcome is harmful. 
Abbreviations: CI, confidence interval; DONE, donepezil; GALA, galantamine; MEMA, 
memantine; NMA, network meta-analysis; NNTB, number needed to treat for an additional 
beneficial outcome; NNTH, number needed to treat for an additional harmful outcome; 
RIVA, rivastigmine; RIVA_O, oral rivastigmine; RIVA_P, transdermal patch rivastigmine 
 
Appendix 11: Overview of the properties of the graphical tools presenting the number 
needed to treat (NNT). 
The characteristics have been categorized to No [--], Yes [], Maybe [()]. 
As shown here, the NNT results can be displayed in several graphs, each of which serves 
different needs and has different properties. A comparison of the plots according to their 
properties is shown in Appendix 11. The NNT results from a single outcome can be 
presented in a bar plot, Cates plot or forest plot. An advantage of both the bar plot and 
forest plot is that they can be used to graphically represent the NNT uncertainty. The Cates 
plot can be recommended to illustrate the meaning of NNT estimates to knowledge users. 
However, the Cates plot is only useful if the effect estimates are statistically significant and 
the estimation uncertainty is not too large. Altman [4] suggested a different version of the 
forest plot presented in this paper, where the NNT values and their CIs are plotted instead 
of the main effect measure values. Another similar plot to the forest plot is the interval 
plot, where the x-axis represents the treatment comparisons and the y-axis depicts the 
effect measure (e.g., RD scale; see Appendix 11). When two outcomes are of interest, the 
bubble plot and scatterplot can be used, where we can assess whether a treatment is 
beneficial in one outcome compared to a certain comparator, and whether it is also 
beneficial or harmful in another outcome when compared to the same comparator. When 
two or more outcomes are available, a rank-heat plot can be considered, which offers the 
opportunity of comparing the results across a variety of treatment comparisons.  
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Key Findings: 
• The number needed to treat (NNT) is an absolute measure of effect used to communicate 
the effectiveness or safety of an intervention and is frequently used in the meta-analytical 
literature. 
What this adds to what is known: 
• Different considerations of calculating a NNT in both pairwise and network meta-analysis 
(NMA), including effect size and assumptions for the control event rate across multiple 
comparisons, may impact NNT results. We present potential ways of calculating NNT in 
(network) meta-analysis, such as mean control event rate () across studies, pooled  
in meta-analysis, expert opinion-based , and range of possible . 
What is the implication? 
• The graphical representation of NNTs from NMA is crucial to ease interpretation of results. 
We present six graphical approaches for NNT from NMA and discuss their properties. We 
suggest the NNT graphical representation in a bar plot, Cates plot or forest plot for a single 
outcome, and in a bubble plot, scatterplot or rank-heat plot for at least two outcomes.  
What should change now? 
• Different plots can be used for different needs. For example, if uncertainty around NNT 
should be considered in decision-making, then a bar plot or a forest plot can be used. When 
multiple outcomes need to be considered, then a rank-heat plot is suggested. For 
communication purposes the Cates plot is suggested if the corresponding effect estimate is 
statistically significant and the confidence interval is not too wide. 
What is new? 
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